Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Drug to prevent preterm birth pulled from market, years after it was shown ineffective

A pharmaceutical company selling the only drug approved to prevent preterm birth said Tuesday that it would withdraw the medicine from the market.

Los Angeles Times

Chinese firm awarded contract after attempting to hack NHS data, minister claims

George Freeman claimed the BGI Group was a “danger point” in science and technology

The Independent UK

Maker of unproven birth drug Makena to pull from US market

The maker of an unproven drug intended to prevent premature births says it will voluntarily remove the product from the United States

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race

Sanofi stock could shine in 2023 as the French pharma tees up a rival to Pfizer's experimental RSV vaccine for newborn babies.

Investors Business Daily

Despite pharma claims, illicit drug shipments to US aren’t full of opioids. It’s generic Viagra

For years, the FDA has defended its efforts to intercept prescription drugs coming from abroad by mail as necessary to keep out dangerous opioids, including fentanyl.

Tribune News Service

European drug agency opposes Amsterdam’s erotic centre plans

EMA says relocation of sex workers to area near its HQ could bring problems associated with red light district

The Guardian - UK

The Best Stock to Buy for Under $100 Right Now

Strong fundamentals and bright prospects of AstraZeneca (AZN), trading below $100 a share, could help investors secure decent risk-adjusted returns on their investments in a choppy market environment. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Could Merck's Next Keytruda-Like Franchise Generate $10 Billion In Sales?

Two of Merck's new drugs could generate north of $10 billion in peak sales, an analyst said Tuesday.

Investors Business Daily

3 Health Care Stocks to Buy in a Heartbeat

The healthcare industry is expanding, fueled by the increasing demand and advancements such as personalized medicines and telehealth. Hence, fundamentally strong healthcare stocks Abbott Laboratories (ABT), Centene (CNC), and McKesson (MCK) might be worth buying in 2023. Read more.

StockNews.com

BridgeBio Soars 52% And Breaks Out After Smashing Expectations In A Dwarfism Study

BridgeBio Pharma smashed Wall Street's expectations in a study of children with dwarfism, leading BBIO stock to break out in massive volume.

Investors Business Daily

Cramlington's Merit enlisted for £150m Moderna vaccine hub scheme

Hundreds of construction jobs will be created through the Moderna Innovation and Technology Centre (MITC) project

Birmingham Post

Trudeau says cocaine licenses are not for selling drug to public

Ottawa (AFP) - Prime Minister Justin Trudeau said Friday he was "surprised" that companies licensed to sell cocaine to pharmacists or hospitals seemed to signal Canada would soon allow legal sales of hard drugs to the public.

AFP

Reporter behind viral Eli Lilly parody account peels back curtain on ‘stupid little tweet’ that helped trigger insulin price cap

Reporter Sean Morrow wants to make sure credit goes to lawmakers working on drug pricing, Graig Graziosi reports

The Independent UK

The implications of Walgreens' decision on abortion pills

Walgreens says it will not start selling an abortion pill in 20 states that had warned of legal consequences if it did that

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating

Kala Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 67 to 83.

StockNews.com

1 Resilient Growth Stock to Buy Now and Hold Forever

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

StockNews.com

3 Biotech Stocks With Potential to Be Big Winners in 2023

The biotech industry is well-positioned to grow strongly, given the ever-rising demand for therapies and favorable government initiatives. Looking at the industry’s long-term prospects, fundamentally strong biotech stocks Amgen (AMGN), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) could emerge as big winners this year. Keep reading….

Investors Business Daily

AstraZeneca's Trading Range Makes This Options Trade Appealing

AztraZeneca (AZN), a U.K. developer of branded prescription therapeutics, ranks first in IBD's diversified medical industry group. But the Composite Rating is only 63. This, combined with the weakening of the market, makes this a solid choice for our familiar short iron condor. With the suspicion that the markets are…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Best Stocks to Own for Passive Income in 2023

The Fed is expected to keep hiking rates to achieve its target inflation rate. Amid rising volatility, investor sentiment toward dividend investing has been improving. Here are three quality dividend-paying stocks, Novartis (NVS), Bristol-Myers Squibb (BMY), and Canon (CAJ), which will ensure a steady passive income stream in 2023. Keep…

WEKU

FDA has new leverage over companies looking for a quicker drug approval

The Food and Drug Administration has new tools to hold drug companies accountable for promises they make about medications. But the agency has yet to show its hand in using this new power.

The Independent UK

‘Hero’ journalist congratulated after Eli Lilly lowers price of insulin after his spoof tweet raised awareness

Eli Lilly’s CEO challenged other pharmaceutical companies to drop insulin prices as well

The New Daily

Victoria tips $10m into mRNA vaccine workforce training

Victoria is pouring $10 million into training Australia's vaccine workforce, ahead of the southern hemisphere's first mRNA production site opening in 2024.

Birmingham Post

Rarecan eyes up to £3m investment this year as cancer platform targets rapidly growing market

The Hexham-based start-up is on the hunt for a lead investor to take it into its next funding round

Investors Business Daily

Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy

Sarepta could snag an accelerated approval for its muscular dystrophy gene therapy, analysts suggested Wednesday as SRPT stock rocketed.

AFP

Vaccine maker Novavax says 'substantial doubt' over future

Washington (AFP) - Covid-19 vaccine maker Novavax raised doubts Tuesday about its ability to continue its business, announcing plans to cut spending after struggles in rolling out its coronavirus jab.

1 … 43 44 45 46

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.